Three-year follow-up after transurethral microwave thermotherapy (TUMT) for benign prostatic hyperplasia using the PRIMUS U + R device.
OBJECTIVE
We report long-term (3 years) follow-up data of transurethral microwave thermotherapy (TUMT) for benign prostatic hyperplasia (BPH) using a lower-power treatment protocol.


METHODS
Ninety-one patients were treated in a 1-h session with the PRIMUS U + R device.


RESULTS
Forty-five of the patients were still on TUMT monotherapy at 3-year follow-up, while 32 received additional therapy for their lower urinary tract symptoms. In patients with monotherapy there was a 45% decrease in international prostate symptom score (IPSS) when compared to pretreatment values. The moderate increase in peak uroflow seen early after TUMT could not be observed after 3 years. No serious side-effects were seen.


CONCLUSIONS
Three years after lower-power TUMT, 49% of patients treated were on TUMT monotherapy, while 35% received additional therapy for their voiding symptoms. Symptom score decreased 45% in patients with TUMT monotherapy concomitant with unchanged uroflow.
Daehlin
L
L
Department of Surgery, University of Bergen, Norway.
Frugård
J
J
D000368:Aged; D000369:Aged, 80 and over; D005069:Evaluation Studies as Topic; D005500:Follow-Up Studies; D006801:Humans; D006979:Hyperthermia, Induced / Q000009:adverse effects / Q000295:instrumentation; D008297:Male; D008872:Microwaves; D008875:Middle Aged; D017060:Patient Satisfaction; D011470:Prostatic Hyperplasia / Q000503:physiopathology / Q000628:therapy*; D012720:Severity of Illness Index; D013995:Time; D013997:Time Factors; D014554:Urination / Q000502:physiology